Shares of Opexa Therapeutics Inc. (OPXA) are on fire, rising as
much as over 500% in intraday trading following news that its stem
cell technology, which is in early preclinical development, has
been acquired by Swiss pharmaceutical giant Novartis AG (NVS) in a
deal exceeding $50 million not including royalties.
view original article